Personalis, Inc. (PSNL) vs Xeris Biopharma Holdings, Inc. (XERS)
A side-by-side comparison of Personalis, Inc. and Xeris Biopharma Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PSNL
Personalis, Inc.
$15.94HealthcareDelayed quote: Oct 6, 2026, 3:45 PM EDT
XERS
Xeris Biopharma Holdings, Inc.
$10.02HealthcareDelayed quote: Oct 6, 2026, 3:45 PM EDT
Total return — PSNL vs XERS
growth of $100 · dividends reinvested · last 7yPSNL -42.4% (-7.6%/yr)XERS -2.6% (-0.4%/yr)XERS compounded faster over this window
PSNL XERS
PSNL vs XERS: by the numbers
- •XERS is the larger company ($1.73B vs $1.70B market cap).
- •Both run net losses; XERS's is the smaller (-5.12% vs -153.84% net margin).
- •XERS grew revenue faster over the past five years (58.33% vs -3.33% CAGR).
Metrics side by side
Valuation
| Metric | PSNL | XERS |
|---|---|---|
| P/S ratio | 24.42 | 5.16 |
| P/B ratio | 7.24 | N/A |
| EV / EBITDA | N/A | 38.65 |
| FCF yield | N/A | 3.20% |
Profitability
| Metric | PSNL | XERS |
|---|---|---|
| Gross margin | 22.65% | 83.34% |
| Operating margin | -126.43% | 10.91% |
| Net margin | -153.84% | -5.12% |
| ROE | -45.58% | N/A |
| ROIC | -42.87% | 12.79% |
Growth (annualized)
| Metric | PSNL | XERS |
|---|---|---|
| Revenue CAGR (5Y) | -3.33% | 58.33% |
| Total return CAGR (5Y) | -1.75% | 33.72% |
Frequently asked
- Which has grown faster, PSNL or XERS?
- Over the past five years, XERS grew revenue faster — PSNL at a -3.33% CAGR versus XERS at 58.33%.
- How have PSNL and XERS total returns compared?
- Over the past 5 years, PSNL delivered -1.75% and XERS delivered 33.72% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Personalis ROEXeris Biopharma ROEPersonalis operating marginXeris Biopharma operating marginPersonalis revenue growthXeris Biopharma revenue growthPersonalis free cash flowXeris Biopharma free cash flow
Personalis & Xeris Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.